

DR. SOLIMAN ABDEL KADER
FAKEEH HOSPITAL COMPANY
(A Saudi Joint Stock Company)

**CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (UNAUDITED)**

For the three-month and nine-month period ended
30 September 2025
together with the

INDEPENDENT AUDITORS' REVIEW REPORT

DR. SOLIMAN ABDEL KADER FAKEEH HOSPITAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

For the nine-months period ended 30 September 2025

Index	Page
Independent auditor's report on review of condensed consolidated interim financial statements	1
Condensed consolidated Interim statement of financial position	2
Condensed consolidated Interim statement of profit or loss and other comprehensive income	3
Condensed consolidated Interim statement of changes in equity	4
Condensed consolidated Interim statement of cash flows	5 - 6
Notes to the condensed consolidated interim financial statements	7 - 24



Ernst & Young Professional Services (Professional LLC)
Paid-up capital (SR 5,500,000 – Five million five hundred thousand Saudi Riyal)
King's Road Tower, 13th Floor
King Abdul Aziz Road (Malek Road)
P.O. Box 1994
Jeddah 21441
Kingdom of Saudi Arabia
Head Office – Riyadh

C.R. No. 4030276644
Tel: +966 12 221 8400
Fax: +966 12 664 4408
ey.ksa@sa.ey.com
ey.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

**To the Shareholders of Dr. Soliman Abdel Kader Fakeeh Hospital Company
(A Saudi Joint Stock Company)**

Introduction

We have reviewed the accompanying interim condensed consolidated statement of financial position of Dr. Soliman Abdel Kader Fakeeh Hospital Company ("the Company") and its subsidiaries (collectively referred to as "the Group") as at 30 September 2025, and the related interim condensed consolidated statement of profit or loss and other comprehensive income for the three-month and nine-month periods ended 30 September 2025, and the related interim condensed consolidated statements of changes in equity and cashflows for the nine-month period then ended, and explanatory notes. Management is responsible for the preparation and presentation of these interim condensed consolidated financial statements in accordance with the International Accounting Standard 34, "*Interim Financial Reporting*" ("IAS 34") as endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these interim condensed consolidated financial statements based on our review.

Scope of Review

We conducted our review in accordance with the International Standard on Review Engagements 2410, "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", as endorsed in the Kingdom of Saudi Arabia. A review of interim financial statement consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 as endorsed in the Kingdom of Saudi Arabia.

Other Matter

The consolidated financial statements for the year ended 31 December 2024 and the interim condensed consolidated financial statements for the three month and nine-month periods ended 30 September 2024 were respectively audited and reviewed by another auditor who expressed an unmodified audit opinion and review conclusion on 11 March 2025 (corresponding to 11 Ramadan 1446H) and 11 November 2024 (corresponding to 9 Jumada Al-Awal 1446H), respectively.

for Ernst & Young Professional Services

Ahmed Ibrahim Reda
Certified Public Accountant
License No. 356

Jeddah: 19 Jumada Al-Ula 1447H
10 November 2025



DR. SOLIMAN ABDEL KADER FAKEEH HOSPITAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION

As at 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

	Notes	30 September 2025 (Unaudited)	31 December 2024 (Audited)
<u>ASSETS</u>			
Property and equipment	5	2,430,987	2,095,843
Right-of-use assets	6.1	459,198	505,338
Intangible assets and goodwill	7	544,376	543,980
Investment properties		387	417
Financial asset at amortized cost		196,011	195,604
Prepayments and other non-current assets		14,302	15,024
Other long-term receivables	8	146,009	117,716
Non-current assets		3,791,270	3,473,922
Inventories		205,637	178,727
Accounts and other receivables	9	1,027,605	895,520
Contract assets	9.2	78,434	68,549
Prepayments and other current assets		158,209	171,122
Cash and cash equivalents	10	391,875	533,785
Current assets		1,861,760	1,847,703
Total assets		5,653,030	5,321,625
<u>EQUITY AND LIABILITIES</u>			
<u>EQUITY</u>			
Share capital	11	232,000	232,000
Treasury shares	11.1	(2,000)	(2,000)
Share premium		1,653,473	1,653,473
Retained earnings		1,224,507	1,061,873
Equity attributable to shareholders of the Company		3,107,980	2,945,346
Non-controlling interests ("NCI")		410,618	374,078
Total equity		3,518,598	3,319,424
<u>LIABILITIES</u>			
Long-term loans	12	334,000	321,500
Lease liabilities	6.2	447,121	481,208
Employees' end of service benefits		292,394	260,689
Non-current liabilities		1,073,515	1,063,397
Short-term loans	12	217,011	215,000
Current portion of lease liabilities	6.2	56,467	60,186
Accounts payables		383,298	372,900
Accrued and other current liabilities		382,255	265,234
Accrued Zakat	13	21,886	25,484
Current liabilities		1,060,917	938,804
Total liabilities		2,134,432	2,002,201
Total equity and liabilities		5,653,030	5,321,625



Mr. Ammar Faqih
Chairman Board of Directors



Dr. Mazen Fakeeh
President



Mr. Panagiotis Chatziantoniou
Group Chief Financial Officer

The accompanying notes 1 to 23 form an integral part of these condensed consolidated interim financial statements.

DR. SOLIMAN ABDEL KADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the three-month and nine-month periods ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

	Notes	For the three-month period ended 30 September		For the nine-month period ended 30 September	
		2025 (Unaudited)	2024 (Unaudited)	2025 (Unaudited)	2024 (Unaudited)
Revenue	14	778,259	713,822	2,291,121	2,048,197
Costs of revenue		(601,013)	(530,003)	(1,757,123)	(1,513,920)
Gross profit		177,246	183,819	533,998	534,277
Other income		3,863	2,848	10,882	10,617
Selling and marketing expenses		(20,619)	(11,469)	(57,646)	(37,375)
General and administrative expenses	15	(80,577)	(67,160)	(235,293)	(211,574)
Impairment loss on accounts receivables	9.1	(5,786)	(3,495)	(19,223)	(9,116)
Operating profit		74,127	104,543	232,718	286,829
Finance costs	16.1	(14,100)	(12,573)	(34,040)	(86,541)
Finance income	16.2	4,729	8,785	17,863	15,815
Profit before zakat		64,756	100,755	216,541	216,103
Zakat	13	(7,645)	(9,034)	(23,914)	(20,822)
Profit for the period		57,111	91,721	192,627	195,281
<u>Other comprehensive income:</u>					
<i><u>Items that will not be reclassified to profit or loss:</u></i>					
Re-measurement loss on defined benefit obligations		--	--	--	--
Total comprehensive income for the period		57,111	91,721	192,627	195,281
Profit / (loss) for the period attributable to:					
- Shareholders of the Parent Company		71,643	93,593	225,966	213,782
- Non-controlling interests		(14,532)	(1,872)	(33,339)	(18,501)
		57,111	91,721	192,627	195,281
Total comprehensive income / (loss) for the period attributable to:					
- Shareholders of the Parent Company		71,643	93,593	225,966	213,782
- Non-controlling interests		(14,532)	(1,872)	(33,339)	(18,501)
		57,111	91,721	192,627	195,281
Earnings per share					
Basic and diluted earnings per share	17	0.31	0.44	0.98	1.00


Mr. Ammar Faqih
Chairman Board of Directors

Dr. Mazen Fakeeh
President

Mr. Panagiotis Chatziantoniou
Group Chief Financial Officer

The accompanying notes 1 to 23 form an integral part of these condensed consolidated interim financial statements.



DR. SOLIMAN ABDEL KADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY

For the nine-month period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

	Attributed to shareholders of the parent					Non-controlling interests	Total equity
	Share capital	Treasury shares	Share premium	Retained earnings	Total		
Balance at 1 January 2024 (Audited)	200,000	--	--	820,255	1,020,255	235,220	1,255,475
<u>Total comprehensive income for the period</u>							
Profit for the period	--	--	--	213,782	213,782	(18,501)	195,281
<u>Transactions with shareholders</u>							
Share capital increase	30,000	--	1,653,473	--	1,683,473	--	1,683,473
Share capital increase - Employee share ownership program (note 11.1)	2,000	--	--	(2,000)	--	--	--
Treasury shares for Employee share ownership program (note 11.1)	--	(2,000)	--	2,000	--	--	--
Additional capital contribution by NCI	--	--	--	--	--	133,697	133,697
Effect of capital increase in subsidiary and dilution of NCI	--	--	--	(27,990)	(27,990)	27,990	--
Balance at 30 September 2024 (Unaudited)	232,000	(2,000)	1,653,473	1,006,047	2,889,520	378,406	3,267,926
Balance at 1 January 2025 (Audited)	232,000	(2,000)	1,653,473	1,061,873	2,945,346	374,078	3,319,424
<u>Total comprehensive income for the period</u>							
Profit for the period	--	--	--	225,966	225,966	(33,339)	192,627
Employee share-based payments reserve charged to profit and loss	--	--	--	5,668	5,668	--	5,668
<u>Transactions with shareholders</u>							
Dividends declared (note 11.2)	--	--	--	(69,000)	(69,000)	--	(69,000)
Additional capital contribution by NCI	--	--	--	--	--	69,879	69,879
Balance at 30 September 2025 (Unaudited)	232,000	(2,000)	1,653,473	1,224,507	3,107,980	410,618	3,518,598
 Mr. Ammar Faqih Chairman Board of Directors  Dr. Mazen Fakeeh President  Mr. Panagiotis Chatziantoniou Group Chief Financial Officer							

The accompanying notes 1 to 23 form an integral part of these interim condensed consolidated financial statements.

DR. SOLIMAN ABDEL KADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

INTERIM CONDENSED CONSOLIDATED INTERIM STATEMENT OF CASH FLOWS

For nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

	Notes	<u>For the nine-month period ended 30 September 2025</u> <u>(Unaudited)</u>	<u>For the nine-month period ended 30 September 2024</u> <u>(Unaudited)</u>
Cash flows from operating activities			
Profit before zakat		216,541	216,103
<i>Adjustments for:</i>			
- Depreciation on property and equipment	5.1	85,146	71,582
- Depreciation on right-of-use assets	6.1	46,121	40,720
- Amortization of Intangible assets		5,581	4,886
- Depreciation on investment properties		30	31
- Provision for employee's end of service benefits		42,938	44,383
- Impairment loss on accounts receivables	9.1	19,223	9,116
- gain on disposal of property and equipment and RoU		(1,917)	(280)
- Non-Cash Share based Payment plan expense	15,11.1	5,668	--
- Discounting impact of DAAM scholarship program		967	1,533
- Net finance costs		16,177	70,726
		<u>436,475</u>	<u>458,800</u>
<i>Changes in operating assets and liabilities:</i>			
- Inventories		(26,910)	(17,761)
- Accounts and other receivables		(151,308)	(95,384)
- Contract assets		(9,885)	(81,888)
- Other long-term receivables		(29,260)	(23,566)
- Prepayments and other current assets		12,913	(31,881)
- Accounts payables		10,398	30,723
- Accrued and other current liabilities		133,454	107,877
Cash generated from operating activities		<u>375,877</u>	<u>346,920</u>
Interest paid		(27,073)	(80,769)
Interest paid on lease	6.2	(23,400)	(24,322)
Employees' end of service benefits paid		(11,233)	(13,428)
Zakat paid	13.b	(27,512)	(20,772)
Net cash generated from operating activities		<u>286,659</u>	<u>207,629</u>
Cash flows from investing activities:			
Additions to property and equipment	5.1	(422,553)	(247,203)
Additions to intangible assets		(3,877)	(4,347)
Prepayments and other non-current assets		722	(16,900)
Interest received	16.2	17,456	15,815
Proceeds from disposal of property and equipment		(667)	856
Net cash used in investing activities		<u>(408,919)</u>	<u>(251,779)</u>
Cash flows from financing activities:			
Additional capital contribution by NCI		69,879	133,697
Net proceeds from the issue of ordinary shares		--	1,683,473
Repayment of principal portion of lease liability	6.2	(35,040)	(31,305)
Proceeds from long-term loans		12,500	80,000
Repayment of long-term loans		--	(786,930)
Dividend paid		(69,000)	--
Net movement in short term loans		2,011	(493,996)
Net cash (used in) / generated from financing activities		<u>(19,650)</u>	<u>584,939</u>
Net (decrease) / increase in cash and cash equivalents		<u>(141,910)</u>	<u>540,789</u>
Cash and cash equivalents at beginning of the period		<u>533,785</u>	<u>214,296</u>
Cash and cash equivalents at the end of the period	10	<u>391,875</u>	<u>755,085</u>

DR. SOLIMAN ABDEL KADER FAKEEH HOSPITAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CASHFLOWS (continued)

For nine-month period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

	Notes	For the nine-month period ended 30 September 2025 <u>(Unaudited)</u>	For the nine-month period ended 30 September <u>2024</u> <u>(Unaudited)</u>
Major non-cash transactions:			
Addition to right-of-use assets and lease liabilities	6.2	<u>26,125</u>	<u>20,546</u>
Borrowing cost capitalized	5.4	<u>23,361</u>	<u>10,585</u>



Mr. Ammar Faqih
Chairman Board of Directors



Dr. Mazen Fakeeh
President



Mr. Panagiotis Chatziantoniou
Group Chief Financial Officer

The accompanying notes 1 to 23 form an integral part of these condensed consolidated interim financial statements.

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

For the nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

1. GENERAL

Dr. Soliman Abdel Kader Fakeeh Hospital Company (the “Parent Company”) is a Saudi Joint Stock Company formed under the laws of the Kingdom of Saudi Arabia and is registered in the Commercial Registry in Jeddah under No. 4030014511 and Unified Identification Number 7001713341 on 11 Rabi II 1398H (20 March 1978). The Parent Company was converted from a Sole Proprietorship to a Saudi closed Joint Stock Company under the Ministerial Decision No. 28 dated 1 Safar 1433H (corresponding to 26 December 2011) approving the announcement of the establishment of Dr. Soliman Abdel Kader Fakeeh Hospital Company (A Saudi “closed Joint Stock Company”). On 27 Duhl Qadah 1445H (corresponding to 4 June 2024), the Parent Company successfully converted from a “Saudi Closed Joint Stock Company” to a “Saudi Joint Stock Company.” Following this, on 28 Duhl Qadah 1445H (corresponding to 5 June 2024), the Parent Company completed its Initial Public Offering (IPO), and its shares were listed on the Tadawul Primary Market, commencing trading under the symbol 4017 and ISIN code SA562GSHUOH7.

These condensed consolidated interim financial statements include assets, liabilities and the results of the operations of the Parent Company and its following subsidiaries collectively referred to as “the Group”. The condensed interim financial statements of the subsidiaries are prepared for the same reporting period and accounting policies as that of the Parent Company.

The Group’s registered office and principal place of business is Jeddah.

The principal activity of the Group is managing, establishing and operating hospitals, clinics, medical, educational and training centers. In addition to the above, the Group is also managing and operating medical services, analysis and radiology laboratory and managing and establishing pharmacies, wholesale and retail of medical equipment, maintenance of IT equipment and software related services.

The Group has three reportable segments including medical services, education and trading & retail business (note 20).

As at 30 September 2025 and 31 December 2024, the Group has investments in the following subsidiaries:

<u>Name of subsidiaries</u>	<u>Country of Incorporation</u>	<u>Effective holding</u>		<u>Principal activities</u>
		<u>2025</u>	<u>2024</u>	
Al-Farabi Special Health Care Company Limited (“Farabi”)	Saudi Arabia	70%	70%	Healthcare service provider
Dr. Soliman Abdel Kader Fakeeh Information Technology Company (Formerly, Kameda Arabia Company Limited)	Saudi Arabia	70%	70%	IT equipment and software services
Dr. Soliman Abdel Kader Fakeeh Family Medicine Centers (“FMH”)	Saudi Arabia	90%	90%	Healthcare service provider
Dr. Soliman Abdel Kader Fakeeh Medical Education Company Limited (“FMEC”)	Saudi Arabia	80%	80%	Medical education service provider
Dr. Mazen Fakeeh Complementary Health Care Company Limited (“FCHC”)	Saudi Arabia	100%	100%	Wholesale and retail of medical equipment
Al Toor Medical Services Company (“Al Toor”)	Saudi Arabia	51%	51%	Healthcare service provider
Saudi Airlines Company for Medical Services (“SMS”)	Saudi Arabia	75%	75%	Healthcare service provider
Al-Faraj Pharmaceutical Medical Company (“Al-Faraj”)	Saudi Arabia	89.82%	89.82%	Trading in pharmaceutical products

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

For the nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

1. GENERAL (continued)

<u>Name of subsidiaries</u>	<u>Country of Incorporation</u>	<u>Effective holding</u>		<u>Principal activities</u>
		<u>2025</u>	<u>2024</u>	
Advanced Horizon Contracting Company ("AHC")	Saudi Arabia	100%	100%	Construction and contracting
Golden Union Medical Company ("GUMC")	Saudi Arabia	100%	100%	Emergency medical services
Dr. Soliman Fakeeh Hospital Medical Company ("DSFH Riyadh")	Saudi Arabia	68.36%	68.36%	Healthcare service provider
White Lines Medical Company ("WLMC")	Saudi Arabia	74.25%	74.25%	Trading in pharmaceutical products
Fakeeh Vision Company Limited ("FVCL")	Saudi Arabia	100%	100%	Trading of spectacles and cosmetics
Dr. Soliman Abdel Kader Fakeeh Home Health Care Company ("FHHC")	Saudi Arabia	100%	100%	Home health care
Advance Lines Medical - ALM	Saudi Arabia	74.25%	74.25%	Trading in pharmaceutical products
Modern Algorithms Solutions for Information Technology Company	Saudi Arabia	100%	--	Healthcare IT software services provider
Masar Dr. Sulaiman Fakeeh Hospital ("MDSFH")	Saudi Arabia	100%	100%	Healthcare service provider
Integrated care solution "ICS"	Saudi Arabia	100%	--	Healthcare IT software services provider
Cyber Immunity Services Company ("CISC")	Saudi Arabia	70%	--	IT equipment and software services

(a) During the current period, the Group established three new subsidiaries registered in the Kingdom of Saudi Arabia. The operations have not yet commenced as of period end.

2. BASIS OF PREPARATION**2.1 Basis of preparation**

These condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standards 34 as issued by International Accounting Standards Board ("IFRS Accounting Standards"), (IAS) 34 "Interim Financial Reporting" that is endorsed in Kingdom of Saudi Arabia and other standards and pronouncements that are issued by the Saudi Organization for Chartered and Professional Accountants ("SOCPA") and should be read in conjunction with the Group's annual consolidated financial statements as at and for the year ended 31 December 2024 ("last annual Financial Statements").

These condensed consolidated interim financial statements do not include all of the information required for a complete set of annual consolidated financial statements prepared in accordance with International Financial Reporting Standards ('IFRS') as endorsed in the Kingdom of Saudi Arabia. However, selected accounting policies and explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last annual consolidated financial statements. In addition, consolidated results for the interim period ended 30 September 2025, are not necessarily indicative of the results that may be expected for the financial year ending 31 December 2025.

Certain comparative figures have been reclassified, wherever considered necessary, for the purpose of comparison and better presentation. Reclassifications are not considered material to the overall interim condensed consolidated financial statements

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

For the nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

2. BASIS OF PREPARATION (continued)**2.2 Basis of measurement**

These condensed consolidated interim financial statements have been prepared under the historical cost basis. Further, the condensed consolidated interim financial statements are prepared using the accrual basis of accounting and the going concern assumption.

2.3 Significant judgments, estimates and assumptions

The preparation of these condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expenses, accompanying disclosures, including disclosure of contingent liabilities. However, uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amount of the asset or liability in the future periods. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognised prospectively.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation of uncertainty were the same as those described in the last annual consolidated financial statements for the year ended 31 December 2024.

2.4 Functional and presentation currency

The Group's condensed consolidated interim financial statements are presented in Saudi Arabian Riyals, which is also the Parent Company's functional currency. For each entity, the Group determines the functional currency, and items included in the financial statements of each entity are measured using that functional currency.

3. NEW STANDARDS, AMENDMENTS TO STANDARDS AND STANDARDS ISSUED BUT NOT YET EFFECTIVE**a) New Standards, interpretations, and amendments issued**

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2024, except for the adoption of new standards effective as of 1 January 2025. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective. Below amendment applies for the first time in 2025 but does not have an impact on the interim condensed consolidated financial statements of the Group.

Lack of exchangeability - Amendments to IAS 21

The amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates specify how an entity should assess whether a currency is exchangeable and how it should determine a spot exchange rate when exchangeability is lacking. The amendments also require disclosure of information that enables users of its financial statements to understand how the currency not being exchangeable into the other currency affects, or is expected to affect, the entity's financial performance, financial position and cash flows. The amendments are effective for annual reporting periods beginning on or after 1 January 2025. When applying the amendments, an entity cannot restate comparative information. The amendments did not have an impact on the Group's financial statements.

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

For the nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

4. MATERIAL ACCOUNTING POLICIES

The accounting policies applied in these interim condensed consolidated financial statements are the same as those applied in the Group's annual consolidated financial statements as at and for the year ended 31 December 2024, except for the following when the Parent Company commenced its share based payment plan:

Share-based payments

Employees (including senior executives) of the Group receive remuneration in the form of share-based payments, whereby employees render services in exchange for equity instruments (equity-settled transactions). Employees working in the business development group are granted share appreciation rights, which are settled in cash (cash-settled transactions).

Equity-settled transactions

The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation.

That cost is recognised in employee benefits expense, together with a corresponding increase in retained earnings, over the period in which the service and, where applicable, the performance conditions are fulfilled (the vesting period). The cumulative expense recognised for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group's best estimate of the number of equity instruments that will ultimately vest. The expense or credit in the statement of profit or loss for a period represents the movement in cumulative expense recognised as at the beginning and end of that period.

Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Group's best estimate of the number of equity instruments that will ultimately vest.

No expense is recognised for awards that do not ultimately vest because non-market performance and/or service conditions have not been met.

When the terms of an equity-settled award are modified, the minimum expense recognised is the grant date fair value of the unmodified award, provided the original vesting terms of the award are met. An additional expense, measured as at the date of modification, is recognised for any modification that increases the total fair value of the share-based payment transaction, or is otherwise beneficial to the employee. Where an award is cancelled by the entity or by the counterparty, any remaining element of the fair value of the award is expensed immediately through profit or loss.

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

For the nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

5. PROPERTY AND EQUIPMENT

5.1 Reconciliation of carrying amounts:

	30 September <u>2025</u> (Unaudited)	31 December <u>2024</u> (Audited)
Carrying amount at beginning of the period / year	2,095,843	1,635,209
Additions during the period / year	422,553	559,261
Disposals during the period / year	(163)	(1,396)
Transfer to Intangibles during the period / year	(2,100)	--
Depreciation charge for the period / year	(85,146)	(97,231)
Carrying amount at the end of the period / year	<u>2,430,987</u>	<u>2,095,843</u>

5.2 Category-wise carrying amounts are as follows:

	30 September <u>2025</u> (Unaudited)	31 December <u>2024</u> (Audited)
Land	387,521	328,692
Buildings and leasehold improvements	939,126	738,923
Medical and support equipment	403,413	323,587
Furniture and fixtures	36,571	32,411
Motor vehicles	18,103	20,466
Office equipment	80,633	19,070
Computers	51,722	32,025
Capital work-in-progress (note 5.3)	513,898	600,669
	<u>2,430,987</u>	<u>2,095,843</u>

5.3 Capital work-in-progress mainly represents the construction work being carried out for the Group's expansion projects and upgrading the existing infrastructure and facilities.

5.4 During the period / year ended 30 September 2025, an amount of SR 23.4 million (2024: SR 20.4 million) was capitalized as borrowing cost.

6. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

6.1 Right-of-use assets

a) Reconciliation of carrying amounts

	30 September <u>2025</u> (Unaudited)	31 December <u>2024</u> (Audited)
<u>Cost:</u>		
Balance at the beginning of the period / year	708,076	679,478
Additions during the period / year	26,125	44,832
Modifications during the period / year	(30,960)	(9,937)
Terminations for the period / year	(11,782)	(6,297)
Balance at the end of the period / year	<u>691,459</u>	<u>708,076</u>

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

For the nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

6. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (continued)**6.1 Right-of-use assets (continued)****a) Reconciliation of carrying amounts (continued)**

	30 September 2025 (Unaudited)	31 December 2024 (Audited)
<u>Accumulated depreciation:</u>		
Balance at the beginning of the period / year	202,738	158,243
Depreciation charge for the period / year	46,121	58,151
Modifications	(10,719)	(7,753)
Terminations for the period / year	(5,879)	(5,903)
Balance at the end of the period / year	232,261	202,738
Carrying Amounts at the end of the period / year	459,198	505,338

6.2 Lease liabilities

	30 September 2025 (Unaudited)	31 December 2024 (Audited)
Balance at the beginning of the period / year	541,394	542,963
Additions during the period / year	26,125	44,832
Interest expenses for the period / year	16,692	28,718
Interest capitalized for the period / year	6,708	4,345
Modifications	(22,713)	2,006
Terminations for the period / year	(6,178)	(505)
Interest paid during the period / year	(23,400)	(33,063)
Payments during the period / year	(35,040)	(47,902)
Balance at the end of the period / year	503,588	541,394

Lease liabilities are presented in the condensed consolidated interim statement of financial positions as follows:

	30 September 2025 (Unaudited)	31 December 2024 (Audited)
Non-current portion of lease liabilities	447,121	481,208
Current portion of lease liabilities	56,467	60,186
	503,588	541,394

7 INTANGIBLE ASSETS AND GOODWILL

	30 September 2025 (Unaudited)	31 December 2024 (Audited)
Goodwill	488,816	488,816
Medical licenses	18,911	20,913
Customer relationships	17,596	18,645
Computer software	6,966	8,604
Software under development	12,087	7,002
	544,376	543,980

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

For the nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

7 INTANGIBLE ASSETS AND GOODWILL (CONTINUED)

The Group performs its annual impairment test in December or when circumstances indicate that the carrying value may be impaired which ever earlier. The Group's impairment test for goodwill is based on value-in-use calculations. The key assumptions used to determine the recoverable amount for the different cash generating units were disclosed in the annual consolidated financial statements for the year ended 31 December 2024. There were no significant changes on key assumptions and sensitivity information disclosed in the annual consolidated financial statements for the year ended 31 December 2024.

8 OTHER LONG-TERM RECEIVABLES

	30 September 2025 (Unaudited)	31 December 2024 (Audited)
Non-current portion of receivables under DAAM scholarship Program	146,009	117,716

9 ACCOUNTS AND OTHER RECEIVABLES

	30 September 2025 (Unaudited)	31 December 2024 (Audited)
Trade receivables	1,140,116	1,011,354
Trade receivables - related parties (note 18)	26,992	15,245
	1,167,108	1,026,599
Less: allowance for impairment losses	(139,503)	(131,079)
	1,027,605	895,520

9.1 The movement of allowance for impairment losses is as follows:

	30 September 2025 (Unaudited)	31 December 2024 (Audited)
Balance at beginning of the period / year	131,079	134,169
Provision for impairment losses during the period / year	19,223	13,475
Written off during the period / year	(10,799)	(16,565)
Balance at end of the period / year	139,503	131,079

9.2 The contract asset primarily relates to operating project contract with customers.

10 CASH AND CASH EQUIVALENTS

Cash and cash equivalents include cash and bank balances.

	30 September 2025 (Unaudited)	31 December 2024 (Audited)
Cash in hand	5,769	2,265
Cash at banks - current accounts	134,106	115,020
Short-term deposits	252,000	416,500
	391,875	533,785

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

For the nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

10 CASH AND CASH EQUIVALENTS (CONTINUED)

At each reporting date, all bank balances are assessed to have low credit risk as they are held with reputable and high credit rating domestic banking institutions and there has been no history of default with any of the Group's bank balances. Therefore, the probability of default based on forward-looking factors and any loss given defaults are considered to be negligible.

- 10.1 Short-term deposits are made at the available short-term deposit rates for varying periods of between one day to three months, depending on the immediate cash requirements of the Group.

11 SHARE CAPITAL

In June 2024, the Parent Company increased its Share Capital from 200 million shares to 232 million shares through (a) issuance of 30 million New Shares offered in Initial Public Offering at the subscription price of SR 57.5 and (b) issuance of 2 million New Shares for Employee Share Ownership Plan funded through the capitalization of SR 2 million from the retained earnings. The legal formalities for such increase were completed and the shares of the Parent Company were listed on 28 Duhl Qadah 1445H (corresponding to 5 June 2024) in the Tadawul Primary Market (note 1).

The issuance of 30 million New Shares has resulted in an amount of SR 1,653.4 million of share premium after the deduction of SR 41.5 million of offering expenses.

As at 30 September 2025, the share capital of the Parent Company comprised of 232 million shares at a nominal value of SR 1 per share (31 December 2024: 232 million shares).

	<u>Pre-Offering</u>		<u>Post-Offering</u>	
	<u>No. of Shares</u>	<u>Amount</u>	<u>No. of Shares</u>	<u>Amount</u>
Dr. Mazen Soliman Abdel Kader Fakeeh	79,984	79,984	71,649	71,649
Mr. Ammar Sulayman A. Faqih	79,984	79,984	71,649	71,649
Dr. Manal Soliman Abdel Kader Fakeeh	39,992	39,992	35,824	35,824
Fakeeh Real Estate Company Limited (A Saudi Limited Liability Company)	20	20	20	20
Al Solimania United Company Limited (A Saudi Limited Liability Company)	20	20	20	20
Employee Share Ownership Plan (note 11.1)	--	--	2,000	2,000
Free Float	--	--	50,838	50,838
	<u>200,000</u>	<u>200,000</u>	<u>232,000</u>	<u>232,000</u>

11.1 Employee Share Ownership Program

On 23 November 2023 (corresponding to 9 Jumada Al Awwal 1445H), the Parent Company's Extraordinary General Assembly approved the issuance of 2 million New Shares through the capitalization of SR 2 million of retained earnings and retain them as treasury shares. These treasury shares will be allocated to the Employee Share Program for the Group in accordance with the applicable terms and conditions. The Employee Share Program will be set-up after the required approvals, to attract and retain outstanding employees. The Extraordinary General Assembly authorized the Board of Directors to implement the Employee Share Program, subject to the related laws.

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

For the nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

11 SHARE CAPITAL (CONTINUED)

During the first quarter of 2025, the Long-Term Incentive Plan “LTIP” detailed policy has been approved by the Board of Directors and will be ratified by the forthcoming EGM in the 4th quarter of 2025. This LTIP cycle will run for 3 years starting from 1st January 2025 and despite the existence of a cliff, the fair value of award will be recognized as Non-Cash Share based Payment during the three years period proportionately and on a quarterly basis.

The LTIP is solely settled through Shares. The number of shares allocated to each employee is communicated at the Grant date to the Employees, however, the actual number of shares at the end of the 3-year period will vary based on the actual vesting conditions as such the LTIP falls within the “Equity-settled share-based payment transactions”.

11.2 During the first quarter of 2025, the Board of Directors recommended a dividend of SAR 69 million, representing SAR 0.30 for each issued share excluding the shares held under the Employee Share Ownership Plan which was subsequently approved by the General Assembly on June 25th 2025 and ultimately paid to eligible shareholders on July 16th 2025.

12 LOANS AND BORROWINGS

The group is financed through facilities from local banks which include both long-term and short-term loans. These facilities are Sharia compliant and are subject to Saudi Arabia interbank Offered Rate “SIBOR” plus a margin. Certain loans are subject to certain bank covenants which are fully compliant at the reporting date.

Movement summary of the loans and borrowings during the period / year is as follows:

	30 September 2025 (Unaudited)	31 December 2024 (Audited)
Balance at beginning of the period / year	536,500	1,720,926
Proceeds during the period / year	804,557	1,496,000
Payments made during the period / year	(790,046)	(2,680,426)
Balance at end of the period / year	551,011	536,500

The term of long-term loans are from 5 to 6 years. The first instalment is payable in Q2 2027.

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

For the nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

13 ZAKAT**a) Charge for the period:**

Zakat included in the condensed consolidated interim statement of profit or loss and other comprehensive income are comprised of the following:

	30 September 2025 (Unaudited)	30 September 2024 (Unaudited)
Charge for the period	23,914	20,822

b) The movement in the accrual for Zakat is as follows:

	30 September 2025 (Unaudited)	31 December 2024 (Audited)
Balance at beginning of the period / year	25,484	24,458
Charge for current period / year	23,914	23,398
Payments during the period / year	(27,512)	(22,372)
Balance at end of the period / year	21,886	25,484

c) Status of assessments

All the below companies have filed their Zakat return for the years up to 31 December 2024 and received unrestricted Zakat certificates for to the same periods.

<u>Company name</u>	<u>Financial years open for Zakat assessment</u>
Dr. Soliman Abdel Kader Fakeeh Hospital Company	2020 - 2024
Al-Farabi Special Health Care Company Limited	2020 - 2024
Dr. Soliman Kader Fakeeh Information Technology Company (Formerly, Kameda Arabia Company Limited)	2020 - 2024
Dr. Soliman Abdel Kader Fakeeh Family Medicine Centers	2020 - 2024
Dr. Soliman Abdel Kader Fakeeh Medical Education Company Limited	2021 - 2024
Dr. Mazen Fakeeh Complementary Health Care Company Limited	2021 – 2024
Al Toor Medical Services Company	2020, 2022 – 2024
Saudi Airlines Company for Medical Services	2020 – 2024
Al-Faraj Pharmaceutical Medical Company	2020 – 2024
Advanced Horizon Contracting Company	2021 – 2024
Golden Union Medical Company	2021 – 2024
Dr. Soliman Fakeeh Hospital Medical Company	2020 – 2024
Dr. Soliman Abdel Kader Fakeeh Home Health Care Company	2023 – 2024
White Lines Medical Company	2023 – 2024
Fakeeh Vision	2023 – 2024

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

For the nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

14 REVENUE***Disaggregation of revenue from contracts with customers***

In the following table, revenue from contracts with customers is disaggregated by major service lines and timing of revenue recognition, all revenue is primarily generated in the Kingdom of Saudi Arabia:

	For the nine-month period ended 30 September 2025 (Unaudited)	For the nine-month period ended 30 September 2024 (Unaudited)
Revenue from Health care operations	2,098,325	1,874,415
Revenue from Medical related services	92,878	79,556
Revenue from Education services	88,674	81,948
Revenue from IT and other services	11,244	12,278
	2,291,121	2,048,197
	For the nine-month period ended 30 September 2025 (Unaudited)	For the nine-month period ended 30 September 2024 (Unaudited)
Timing of revenue recognition		
Point in time	1,450,086	1,273,472
Over time	841,035	774,725
Revenue from contracts with customers	2,291,121	2,048,197

15 GENERAL AND ADMINISTRATIVE EXPENSES

	For the nine-month period ended 30 September 2025 (Unaudited)	For the nine-month period ended 30 September 2024 (Unaudited)
General and administrative expenses	229,625	211,574
Non-Cash Share based Payment (Note 11.1)	5,668	--
	235,293	211,574

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

For the nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

16 FINANCE COST AND INCOME**16.1 Finance Costs**

	For the nine-month period ended 30 September 2025 (Unaudited)	For the nine-month period ended 30 September 2024 (Unaudited)
Interest expenses – loan	17,348	62,219
Interest expenses – lease liabilities	16,692	24,322
	34,040	86,541

16.2 Finance Income

Finance income is recognized using effective interest method. Time deposits are placed with financial institutions in the Kingdom of Saudi Arabia; these deposits are sharia compliant.

	For the nine-month period ended 30 September 2025 (Unaudited)	For the nine-month period ended 30 September 2024 (Unaudited)
Income from deposits and government Sukuk	17,863	15,815

17 EARNINGS PER SHARE

Basic earnings per share (EPS) is calculated by dividing profit for the period attributable to ordinary equity holders of the Parent Company by the weighted average number of ordinary shares in issue outstanding during the period.

	For the nine-month period ended 30 September 2025 (Unaudited)	For the nine-month period ended 30 September 2024 (Unaudited)
Profit for the period attributable to ordinary equity holders of the Parent	225,966	213,782
Weighted average number of ordinary shares in issue	230,000	212,920
Basic and diluted earnings per share	0.98	1.00

17.1 Weighted-average number of ordinary shares

	30 September 2025 (Unaudited)	30 September 2024 (Unaudited)
Issued shares at 1 January	232,000	200,000
Effect of shares issued in June (note 11)	--	13,781
Effect of treasury shares (note 11.1)	(2,000)	(861)
Weighted average number of shares	230,000	212,920

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

For the nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

18 RELATED PARTY TRANSACTIONS AND BALANCES

The Group, in the normal course of business, enters into transactions with other entities that fall within the definition of a related party contained in International Accounting Standard 24 as endorsed in KSA. Related parties comprise of the shareholders of the Group, being parent Company, its subsidiaries and associates, and other companies with common directorship with significant influence on other companies and key management personnel. Transactions with related parties arise mainly from goods/services received and various business arrangements undertaken at management approved contractual terms.

Transactions with key management personnel***Key management personnel compensation***

a) Key management personnel remuneration and compensation comprised of the following:

	30 September 2025	30 September 2024
	(Unaudited)	(Unaudited)
Short-term employee benefits	18,963	12,753
Board of Directors' and related committee remuneration	1,080	990
Board of Directors' Other remuneration	9	141
Post-employment benefits	822	2,289
	<u>20,874</u>	<u>16,173</u>

Related party relationships

Name	Relationship
<u>Entities with joint control of, or significant influence over, the entity</u>	
Fakeeh Academic Medical Centre – Dubai	Under common ownership of the Group's controlling shareholder
Diagnostic Elite Company Limited	Under common ownership of the Group's controlling shareholders
Cold Sky Energy Company Limited (Halaa Renewable energy)	Under common ownership of the Group's controlling shareholders
Soliman Mazen Soliman Fakeeh Restaurant Company	Under common ownership of the Group's controlling shareholders
<u>Controlling shareholders</u>	
Dr. Mazen Soliman Abdel Kader Fakeeh	Shareholder and President
Mr. Ammar Sulayman A. Faqih	Shareholder
Dr. Manal Soliman Abdel Kader Fakeeh	Shareholder
<u>Other related parties</u>	
Saudi Arabian Airlines Corporation Group	Non - controlling Shareholder

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

For the nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

18. RELATED PARTY TRANSACTIONS AND BALANCES (continued)

b) Related party transactions

<u>Name</u>	<u>Nature of transactions</u>	<u>Amount of transactions</u>	
		30 September 2025 (Unaudited)	30 September 2024 (Unaudited)
	Payments made on behalf of the related party	713	359
Fakeeh Academic Medical Centre – Dubai	Royalty Charges	1,800	1,800
	Revenue	3,523	1,159
	SLA Charges	900	900
Soliman Mazen Soliman Fakeeh Restaurant Company	Lease rental payments	558	393
	Revenue	26,645	35,658
Saudi Arabian Airlines Corporation Group	Lease rental payments	23,089	18,840
	Payments made on behalf of the related party	1,930	1,417
	Lease rental payments	9,045	10,833
Dr. Mazen Soliman Abdel Kader Fakeeh	Collections	4,914	--
	Payments made on behalf of the related party	769	2,334
	Lease rental payments	9,045	10,833
Mr. Ammar Sulayman A. Faqih	Collections	2,145	--
	Payments made on behalf of the related party	355	1,126
	Lease rental payments	6,581	7,455
Dr. Manal Soliman Abdel Kader Fakeeh	Collections	268	--
	Payments made on behalf of the related party	38	455
Diagnostic Elite Company	Purchases	3,540	2,484
Cold Sky Energy Company Limited (Halaa Renewable energy)	Purchases	--	429

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

For the nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

18. RELATED PARTY TRANSACTIONS AND BALANCES (continued)

c) Related party closing balances

<u>Name</u>	<u>Balance as of</u>	
	30 September 2025 (Unaudited)	31 December 2024 (Audited)
<u>Due from related parties – (Trade and other receivables)</u>		
Saudi Arabian Airlines Corporation Group	29,253	35,506
Fakeeh Academic Medical Centre – Dubai	11,675	6,166
Dr. Manal Soliman Abdel Kader Fakeeh	1,805	2,035
Dr. Mazen Soliman Abdel Kader Fakeeh	749	4,894
Mr. Ammar Sulayman A. Faqih	346	2,136
Soliman Mazen Soliman Fakeeh Restaurant Company	199	165
	<u>44,027</u>	<u>50,902</u>
<u>Due to related parties – (Accounts payables, Accrued and other current liabilities)</u>		
Saudi Arabian Airlines Corporation Group	25	318
	<u>25</u>	<u>318</u>

19 COMMITMENTS AND CONTINGENCIES

As at 30 September 2025 the Group has:

- Outstanding letters of guarantee amounting to SR 31.9 million (31 December 2024: SR 26.1 million).
- Outstanding letters of credit amounting to SR 11.6 million (31 December 2024: SR 63.8 million).
- Commitments for capital work in progress of SR 198.3 million (31 December 2024: SR 374 million) mainly relating to construction, renovation and upgradation of buildings.

As at 30 September 2025, there are no significant litigations and claims against the Group.

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

For the nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

20 BUSINESS SEGMENTS

As the operations of the Group are conducted in the Kingdom of Saudi Arabia, accordingly, for management purposes, the Group is organized into business units based on its products and services and has three reportable segments. Operating segments is determined based on the Group's internal reporting to the Chief Operating Decision Maker ("CODM"). The CODM has been determined to be the President as he is primarily responsible for the allocation of resources to segments and the assessment of the performance of each of the segments. The CODM uses underlying income as reviewed at monthly Executive Committee and Performance meetings as the key measure of the segments' results as it reflects the segments' performance for the period under evaluation. Revenue and segment profit is a consistent measure within the Group. The identified key segments are medical services, education, trading and retail.

Information regarding the results of each reportable segment is included below. Performance is measured based on segment revenues, as included in the internal management reports that are reviewed by the top management. The following table presents segment information (assets, liabilities, revenue and net income) for each of the business segments as at and for the three-month period ended 30 September:

30 September 2025 (Unaudited)	Reportable Segments				Total
	Medical services	Education	Trading, Retail & Others	Un-Allocated	
Revenues	2,126,534	89,640	325,614	--	2,541,788
Inter-segment revenue eliminations	(15,026)	(967)	(234,674)	--	(250,667)
Segment revenue	2,111,508	88,673	90,940	--	2,291,121
Direct costs	(1,625,626)	(45,402)	(284,697)	--	(1,955,725)
Inter-segment direct costs	15,026	--	183,576	--	198,602
Segment cost	(1,610,600)	(45,402)	(101,121)	--	(1,757,123)
Segment gross profit	500,908	43,271	(10,181)	--	533,998
Operating expenses	--	--	--	(292,939)	(292,939)
Impairment loss on accounts receivables	(13,510)	(1,260)	(4,453)	--	(19,223)
Other income	--	--	--	10,882	10,882
Operating profit	487,398	42,011	(14,634)	(282,057)	232,718
Finance cost	--	--	--	(34,040)	(34,040)
Finance income	--	--	--	17,863	17,863
Zakat	--	--	--	(23,914)	(23,914)
Profit for the period	487,398	42,011	(14,634)	(322,148)	192,627
30 September 2025 (Unaudited)					
Total assets	4,629,530	237,952	785,548	--	5,653,030
Total liabilities	1,626,413	142,602	334,213	31,204	2,134,432

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

For the nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

20. BUSINESS SEGMENTS (continued)

30 September 2024 (Unaudited)	<u>Reportable Segments</u>				<u>Total</u>
	<u>Medical services</u>	<u>Education</u>	<u>Trading, Retail & Others</u>	<u>Un-Allocated</u>	
Revenues	1,907,993	83,992	171,617	--	2,163,602
Inter-segment revenue eliminations	(1,344)	(2,044)	(112,017)	--	(115,405)
Segment revenue	<u>1,906,649</u>	<u>81,948</u>	<u>59,600</u>	<u>--</u>	<u>2,048,197</u>
Direct costs	(1,437,237)	(43,422)	(117,284)	--	(1,597,943)
Inter-segment direct costs	1,344	--	82,679	--	84,023
Segment cost	<u>(1,435,893)</u>	<u>(43,422)</u>	<u>(34,605)</u>	<u>--</u>	<u>(1,513,920)</u>
Segment gross profit	<u>470,756</u>	<u>38,526</u>	<u>24,995</u>	<u>--</u>	<u>534,277</u>
Operating expenses	--	--	--	(248,949)	(248,949)
Impairment loss on accounts receivables	(6,731)	(1,260)	(1,125)	--	(9,116)
Other income	--	--	--	10,617	10,617
Operating profit	<u>464,025</u>	<u>37,266</u>	<u>23,870</u>	<u>(238,332)</u>	<u>286,829</u>
Finance Income	--	--	--	15,815	15,815
Finance cost	--	--	--	(86,541)	(86,541)
Zakat	--	--	--	(20,822)	(20,822)
Profit for the period	<u>464,025</u>	<u>37,266</u>	<u>23,870</u>	<u>(329,880)</u>	<u>195,281</u>
31 December 2024 (Audited)					
Total assets	<u>4,398,183</u>	<u>180,407</u>	<u>743,035</u>	<u>--</u>	<u>5,321,625</u>
Total liabilities	<u>1,673,374</u>	<u>101,069</u>	<u>199,883</u>	<u>27,875</u>	<u>2,002,201</u>

The Group's top management reviews internal management reports of each strategic business unit at least quarterly. Segment results that are reported to the top management include items directly attributable to a segment as well as those that can be allocated on a reasonable basis.

21 FAIR VALUE OF FINANCIAL ASSETS AND FINANCIAL LIABILITIES

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction takes place either:

- In the accessible principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous accessible market for the asset or liability
- Fair value information of the Group's financial instruments is analysed below:

DR. SOLIMAN ABDELKADER FAKEEH HOSPITAL COMPANY

(A Saudi Joint Stock Company)

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)**

For the nine-months period ended 30 September 2025

(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

21. FAIR VALUE OF FINANCIAL ASSETS AND FINANCIAL LIABILITIES (continued)

The Group uses the following hierarchy for determining and disclosing the fair value of financial instruments:

Level 1: quoted prices in active markets for the same or identical instrument that an entity can access at the measurement date;

Level 2: quoted prices inactive markets for similar assets and liabilities or valuation techniques for which all significant inputs are based on observable market data; and

Level 3: valuation techniques for which any significant input is not based on observable market data.

There were no transfers between level 1 and level 3 during the three-month period 30 September 2025 (31 December 2024: nil). There were no financial assets or financial liabilities classified under level 2 (31 December 2024: nil).

There were no changes in valuation techniques during the period. As at 30 September 2025, the financial assets of the Group are comprised of financial assets at amortized cost, prepayments and other current assets, accounts and other receivables, contract assets and cash and cash equivalents which are recorded at amortised cost and their carrying values approximates their fair values. The Group's financial liabilities include long-term and short-term loans, accounts payable, accruals and other liabilities

22 SUBSEQUENT EVENTS

On 24 October 2025 the Board of Directors, approved the commencement of negotiations with the potential sellers in Dr. Mohammed bin Rashed Al-Faqih & Partners Company (the "Selling Shareholders") regarding a potential acquisition of a majority stake in Dr. Mohammed bin Rashed Al-Faqih & Partners Company (the "Proposed Transaction"). At this stage, it is difficult to determine the precise financial impact of the proposed transaction; any material developments will be announced in due course.

On 4th of November 2025, the Board of Directors has approved the initiation of negotiations to acquire a majority stake in Diagnostic Elite Company ("DE"). The completion of this transaction will then be subject to the necessary regulatory approvals as well as from the Shareholders General Assembly, applicable to a transaction between related parties (DSFH and Sulaiman Abdul-Qader Fakeeh Real Estate Co). Further material developments will be announced in accordance with applicable regulations.

23 DATE OF AUTHORIZATION FOR ISSUE

The interim condensed consolidated financial statements were approved and authorized for issue by the Board of Directors of Parent Company on 4 November 2025, corresponding to 13 Jumada Al-Ula 1447H.



Mr. Ammar Faqih
Chairman Board of Directors



Dr. Mazen Fakeeh
President



Mr. Panagiotis Chatziantoniou
Group Chief Financial Officer